Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6474)	6/4/2002 5:38:46 PM
From: Ian@SI	Read Replies (3) \| Respond to of 52153

Edited to add RS opinion. 5:50PM Tuesday If we can believe Briefing.Com, they also seem to think that MLNM is cheap at current prices. It would also appear that the stock is just entering that zone (2 years before and after first Q of profitability) where investors stand to make the largest profit. FWIW, Ian ++++++++++++++++++++++ 10:02 ET Millennium Pharm sees Integrilin growth of 30%, profitability in 2 years (MLNM) 13.05 -0.58: -- Update -- Hearing from a source listening to MLNM's presentation at the Needham Biotech conference that the co expects Integrilin sales to grow 30% annually for the next 3 years (we're told the previous expectation was for 25% sales growth), and expects to bring 1-2 products to mkt per year and 3-4 products per year to the clinic by 2005. In addition, co says they will have $1.7 bln in cash by year-end, and expects to be profitable in 2 years (current consensus sees losses through 2003-04). ++++++++++++++ 14:33 ET Millennium Pharm: positive comments by Robbie (MLNM) 13.32 -0.31: -- Update -- Robertson Stephens says MLNM is the most compelling stock in their coverage universe, and sees a significant flow of potentially positive catalysts for the remainder of the year, including Phase II data on MLN-09 and MLN-02 in August, CRUSADE data at AHA in Nov, and final Phase II data on MLN-341 in multiple myeloma at ASH in Dec; firm also notes that the co trades for $3.2 bln yet has $2 bln in cash.

To: Biomaven who wrote (6474)	6/5/2002 1:18:48 PM
From: David Howe	Read Replies (1) \| Respond to of 52153

Thanks Peter. << My view is that MLNM is cheap at these prices, particularly if you take a multi-year view. >> It's been painful, but I've adopted the the "multi-year view" for most of my portfolio at this point. <g> MLNM looks like it has great potential. Who knows, maybe they and other biotechs will hit their prime in a few years just as the market achieves bull market status once again. If that happens, please remind me to take some profits. <g> Dave